Hey guys-
Just wanted to now if any of you are on the denufosol trial?? Exciting news coming down the pike from several people....
Increases in pfts on the drug are unbelievable (as much as 30%) and there is evidence to suggest it can efflux glutathione into the extracellular lung space!!!!
I really want to hear from those who are on it. Although it is double blind, apparently there is no debating who is and who is not on the drug.
Please let us know.
mandy
Hi I just wanted to edit this and make sure all understand what denufosol does. It does not correct the cftr channel but instead creates a new channel which allows for normal efflux of salt, water, and yes, glutathione (they think).
<b>Denufosol tetrasodium is a selective P2Y2 agonist designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms by activating an alternative ion channel that acts in the same way as the defective ion channel normally would in moving salt and water to the surface of the airways.
This is a critical development for CF patients and could represent an entirely new way to correct the basic defect in cells that line the airways, said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation.</b>
Just wanted to now if any of you are on the denufosol trial?? Exciting news coming down the pike from several people....
Increases in pfts on the drug are unbelievable (as much as 30%) and there is evidence to suggest it can efflux glutathione into the extracellular lung space!!!!
I really want to hear from those who are on it. Although it is double blind, apparently there is no debating who is and who is not on the drug.
Please let us know.
mandy
Hi I just wanted to edit this and make sure all understand what denufosol does. It does not correct the cftr channel but instead creates a new channel which allows for normal efflux of salt, water, and yes, glutathione (they think).
<b>Denufosol tetrasodium is a selective P2Y2 agonist designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms by activating an alternative ion channel that acts in the same way as the defective ion channel normally would in moving salt and water to the surface of the airways.
This is a critical development for CF patients and could represent an entirely new way to correct the basic defect in cells that line the airways, said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation.</b>